<ul><li>CrossBridge Bio is developing dual-payload ADCs to target tumor heterogeneity and resistance in cancer treatment.</li><li>Their lead candidate, CBB-120, utilizes two different payloads within a single ADC to maximize therapeutic effect.</li><li>CrossBridge Bio aims to enhance efficacy while reducing side effects by delivering both agents together in a targeted manner.</li><li>The company's highly stable linkers ensure precise drug release, mitigating safety issues associated with ADCs.</li></ul>

CrossBridge Bio: Innovating Cancer Treatment with Dual-Payload ADCs

Discover more